Evotec SE (NASDAQ:EVO) Short Interest Down 10.7% in November

Evotec SE (NASDAQ:EVO) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 401,600 shares, a drop of 10.7% from the November 15th total of 449,700 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 197,200 shares, the short-interest ratio is presently 2.0 days.

Analyst Ratings Changes

EVO has been the topic of a number of recent research reports. Jefferies Financial Group downgraded Evotec from a “buy” rating to a “hold” rating and lowered their target price for the company from $8.70 to $3.80 in a research report on Monday, October 7th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Evotec in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $5.93.

Evotec Price Performance

Shares of EVO stock traded up $0.11 on Tuesday, reaching $4.78. The stock had a trading volume of 159,667 shares, compared to its average volume of 132,854. Evotec has a 12 month low of $2.85 and a 12 month high of $12.00. The firm’s 50-day moving average is $4.22 and its two-hundred day moving average is $4.14. The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43.

Institutional Trading of Evotec

Several institutional investors and hedge funds have recently bought and sold shares of EVO. Wellington Management Group LLP raised its position in shares of Evotec by 29.7% in the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock valued at $9,616,000 after purchasing an additional 602,858 shares during the period. Clear Harbor Asset Management LLC acquired a new position in Evotec in the 3rd quarter valued at about $104,000. Mediolanum International Funds Ltd bought a new position in Evotec in the 3rd quarter valued at about $512,000. Novo Holdings A S acquired a new stake in Evotec during the second quarter worth approximately $71,183,000. Finally, DCF Advisers LLC boosted its holdings in shares of Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after acquiring an additional 67,156 shares during the period. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.